Amerikan Üroloji Derneği, Kastrasyon Dirençli Prostat Kanseri için Kılavuz yayımladı…
New AUA Guideline for Castration-Resistant Prostate Cancer
Nick Mulcahy – May 09, 2013
The American Urological Association (AUA) has issued a new guideline for the management of castration-resistant prostate cancer (CRPC) that provides a “rational basis” for treatment decisions.
Those decisions are now “complex” because a group of treatment options for metastatic disease has emerged in a short period of time, according to a press release issued at AUA 2013 Annual Scientific Meeting, held in San Diego, California.
The treatment options in metastatic CRPC (mCRPC) include 4 new therapies that have been approved since 2010: sipuleucel-T (Provenge, Dendreon), cabazitaxel (Jevtana, sanofi-aventis), abiraterone (Zytiga, Janssen), and enzalutamide (Xtandi, Astellas/Medivation). These therapies, along with docetaxel (approved in 2004), have all been shown to improve overall survival in metastatic disease.
“Prior to 2004, once patients failed primary androgen deprivation, treatments were administered solely for palliation,” write the guideline authors, led by Michael S. Cookson, MD, from Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.
The guidelines are much needed, according to a clinician not involved with their writing. “There is a lack of clarity as to the best method for treating castration-resistant prostate cancer,” said Willie Underwood III, MD, MPH, from the Roswell Park Cancer Institute in Buffalo, New York.
The guidance is especially important given the publicity that has accompanied the new therapies, as well as their cost, he told Medscape Medical News in an interview. “When a drug comes out with a lot of hype, every patient wants that drug.”
A large part of the new guideline is recommendations for 6 different types of patients. These “index” patients represent the most common clinical scenarios in men whose prostate cancer is not responsive to traditional androgen-deprivation therapy.
The profiles of the index patients comprise symptoms, performance status, the presence or absence of metastases, and whether or not docetaxel has been administered.
The guideline authors acknowledge that treatment is rapidly changing, and advise clinicians to use it in conjunction with the “current literature” and an individual patient’s treatment goals.
The following are the index patients and the associated recommendations.
Index Patient 1: Asymptomatic Nonmetastatic CRPC
|
Profile |
|
The typical patient has a rising prostate-specific antigen (PSA) level and no radiologic evidence of metastatic prostate cancer. He is also required to have castrate levels of testosterone (less than 50 ng/mL). |
|
Treatment recommendations |
|
Observation with continued androgen deprivation |
|
First-generation antiandrogens (flutamide, bicalutamide, and nilutamide) or first-generation androgen-synthesis inhibitors (ketoconazole plus steroid) to patients unwilling to accept observation |
|
Discussion |
|
No treatment has been shown to improve overall survival in these men. “Since all agents have potential side effects…we must first do no harm,” write the authors. |
Index Patient 2: Asymptomatic or Minimally Symptomatic mCRPC Without Previous Docetaxel Chemotherapy
|
Profile |
|
These patients have “a rising PSA in the setting of castrate levels of testosterone” and metastatic disease documented on radiographic imaging. |
|
Treatment recommendations |
|
Abiraterone plus prednisone, docetaxel, or sipuleucel-T |
|
First-generation antiandrogen therapy or ketoconazole plus steroid or observation to patients who do not want or cannot have one of the standard therapies |
|
Discussion |
|
The 3 standard therapies are approved by the US Food and Drug Administration for this indication and improved overall survival in randomized clinical trials. There are no direct comparison studies to inform optimal sequencing. “As a general principle, it is preferable to give the least toxic agent first,” the authors note. |
Index Patient 3: Symptomatic mCRPC With Good Performance Status and No Previous Chemotherapy
|
Profile |
|
These patients have a rising PSA level in the setting of castrate levels of testosterone. Their symptoms should be related to prostate cancer alone (and not other conditions), and might include pain. |
|
Treatment recommendations |
|
Docetaxel |
|
Abiraterone plus prednisone |
|
Ketoconazole plus steroid, mitoxantrone, or radionuclide therapy for patients who do not want or cannot have one of the standard therapies |
|
Discussion |
|
Sipuleucel-T immunotherapy is not recommended in symptomatic disease, the authors note. |
Index Patient 4: Symptomatic mCRPC With Poor Performance Status and No Previous Docetaxel Chemotherapy
|
Profile |
|
Clinical trials have generally excluded patients with a poor performance status (ECOG 3 or 4); as a result, data guiding their management are extrapolated from randomized trials of healthier patients. |
|
Treatment recommendations |
|
Abiraterone plus prednisone |
|
Ketoconazole plus steroid or radionuclide therapy to patients who are unable or unwilling to receive abiraterone plus prednisone |
|
Docetaxel or mitoxantrone chemotherapy in select cases, specifically when performance status is directly related to the cancer |
Patient 5: Symptomatic mCRPC With Good Performance Status and Previous Docetaxel Chemotherapy
|
Profile |
|
A focus of therapy should be to maintain the excellent performance status without significant toxicity from additional therapy. |
|
Treatment recommendations |
|
Abiraterone plus prednisone, cabazitaxel, or enzalutamide |
|
If the patient received abiraterone plus prednisone prior to docetaxel chemotherapy, offer cabazitaxel or enzalutamide |
|
Ketoconazole plus steroid if abiraterone plus prednisone, cabazitaxel, or enzalutamide is unavailable |
|
Retreatment with docetaxel for patients who were benefiting from but discontinued treatment with docetaxel because of reversible adverse effects |
|
Discussion |
|
Abiraterone plus prednisone and enzalutamide appear to provide clinical benefit equivalent to (if not superior to) additional intravenous chemotherapy with an agent such as cabazitaxel. These 2 therapies have “significantly less acute toxicity and no apparent cumulative toxicity” over prolonged periods, say the authors. |
Index Patient 6: Symptomatic mCRPC With Poor Performance Status and Previous Docetaxel Chemotherapy
|
Profile |
|
“Treatment given in the last months of life may delay access to end-of-life care, increase costs, and add unnecessary symptom management. Patients with poor performance status (ECOG 3 or 4) should not be offered further treatment,” write the authors. |
|
Treatment recommendations |
|
Palliative care |
|
For selected patients, offer treatment with abiraterone plus prednisone, enzalutamide, ketoconazole plus steroid, or radionuclide therapy |
|
Discussion |
|
There is insufficient evidence demonstrating a treatment benefit in this patient population. |
Because the skeletal system is the most common site for prostate cancer metastasis, the guideline also makes recommendations regarding bone health.
Bone Health
|
Treatment recommendations |
|
Offer preventative treatment (e.g., supplemental calcium, vitamin D) for fractures |
|
Choose either denosumab or zoledronic acid as preventative treatment for skeletal-related events |
“Prostate cancer deaths are typically the result of mCRPC, a painful disease,” said Dr. Cookson in a press statement. “In recent years, a number of new treatments and therapeutic agents have entered the market that have been shown to minimize adverse effects and pain and prolong survival in some patients, but the fact remains that mCRPC is the terminal stage of prostate cancer.”
Medscape Medical News © 2013 WebMD, LLC
Send comments and news tips to [email protected].
Cite this article: New AUA Guideline for Castration-Resistant Prostate Cancer. Medscape. May 09, 2013.